Hemodynamic and metabolic effects of vasodilators, nitrates, hydralazine, prazosin and captopril in chronic ischemic heart failure.
Vasodilators like nitrates, hydralazine, captopril and prazosin all improve left ventricular function of patients with chronic ischemic heart failure. The influence of these vasodilator agents on coronary hemodynamics and myocardial oxygen consumption, however may not be similar. With nitrates and captopril, improved left ventricular function is associated and with decreased myocardial oxygen consumption; in contrast, with prazosin or hydralazine no consistent or significant change in myocardial oxygen consumption is observed. Thus, the metabolic cost for the improved left ventricular function with these vasodilator agents is not similar.
D002216:Captopril / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D007773:Lactates / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption; D011224:Prazosin / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*
D007773:Lactates; D014665:Vasodilator Agents; D006830:Hydralazine; D002216:Captopril; D007548:Isosorbide Dinitrate; D011224:Prazosin